SUBSCRIPTION AGREEMENTSubscription Agreement • August 1st, 2018 • 20/20 GeneSystems, Inc. • Services-testing laboratories • Delaware
THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK. THIS INVESTMENT IS SUITABLE ONLY FOR PERSONS WHO CAN BEAR THE ECONOMIC RISK FOR AN INDEFINITE PERIOD OF TIME AND WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. FURTHERMORE, INVESTORS MUST UNDERSTAND THAT SUCH INVESTMENT IS ILLIQUID AND IS EXPECTED TO CONTINUE TO BE ILLIQUID FOR AN INDEFINITE PERIOD OF TIME. NO PUBLIC MARKET EXISTS FOR THE SECURITIES, AND NO PUBLIC MARKET IS EXPECTED TO DEVELOP FOLLOWING THIS OFFERING.
AMENDMENT TO ISSUER AGREEMENTIssuer Agreement • August 1st, 2018 • 20/20 GeneSystems, Inc. • Services-testing laboratories • New York
THIS AMENDMENT LETTER (the “Letter”) is entered into as of July 31, 2018 (the “Effective Date”) by and among 20/20 GeneSystems, Inc. (the “Company”) and SI Securities, LLC (“SI Securities”, and together with Company, the “Parties”).
